(DAPT‐STEMI): randomised, multicentre, non‐inferiority trial. BMJ 2018; 363:k3793.57 57 Luca G de, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short‐term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new‐generation stent (REDUCE trial). EuroIntervention 2019; 15:e990–e998.
58 58 Kim B‐K, Hong S‐J, Cho Y‐H, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020; 323:2407–16.
59 59 Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High‐Risk Patients after PCI. N Engl J Med 2019; 381:2032–42.
60 60 Khan SU, Singh M, Valavoor S, et al. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug‐Eluting Stents: A Systematic Review and Network Meta‐Analysis. Circulation 2020; 142:1425–36.
61 61 Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012; 34:44–55.
62 62 Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368:1303–13.
63 63 Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330–41.
64 64 Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318–29.
65 65 Franchi F, Rollini F, Rivas A, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST‐Segment‐Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation 2019; 139:1661–70.
66 66 Grimfjärd P, Lagerqvist B, Erlinge D, et al. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 2019; 5:151–7.
67 67 Ubaid S, Ford TJ, Berry C, et al. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost 2019; 119:1171–81.
68 68 Zeymer U, Wienbergen H. A review of clinical trials with eptifibatide in cardiology. Cardiovasc Drug Rev 2007; 25:301–15.
69 69 Luca G de, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST‐segment elevation myocardial infarction: a meta‐analysis of randomized trials. JAMA 2005; 293:1759–65.
70 70 Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST‐elevation myocardial infarction: a European meta‐analysis on individual patients' data with long‐term follow‐up. Eur Heart J 2007; 28:443–9.
71 71 Ellis SG, Tendera M, Belder MA de, et al. Facilitated PCI in patients with ST‐elevation myocardial infarction. N Engl J Med 2008; 358:2205–17.
72 72 van't Hof AWJ, Berg J ten, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST‐elevation myocardial infarction undergoing primary angioplasty (On‐TIME 2): a multicentre, double‐blind, randomised controlled trial. The Lancet 2008; 372:537–46.
73 73 Berg JM ten, van 't Hof AWJ, Dill T, et al. Effect of early, pre‐hospital initiation of high bolus dose tirofiban in patients with ST‐segment elevation myocardial infarction on short‐ and long‐term clinical outcome. J Am Coll Cardiol 2010; 55:2446–55.
74 74 Dannenberg L, Wolff G, Naguib D, et al. Safety and efficacy of Tirofiban in STEMI‐patients. Int J Cardiol 2019; 274:35–9.
75 75 Zhang Z, Li W, Wu W, et al. Myokardreperfusion mit Tirofibaninjektion via Aspirationskatheter: Wirksamkeit und Sicherheit bei STEMI‐Patienten mit hoher Thrombuslast [Myocardial reperfusion with tirofiban injection via aspiration catheter: Efficacy and safety in STEMI patients with large thrombus burden]. Herz 2020; 45:280–7.
76 76 Gibson CM, Kirtane AJ, Murphy SA, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)‐TIMI 34 trial. Am Heart J 2006; 152:668–75.
77 77 Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST‐segment elevation myocardial infarction: results of the EVA‐AMI Trial. J Am Coll Cardiol 2010; 56:463–9.
78 78 Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 2010; 56:470–5.
79 79 Savonitto S, De Luca G, Goldstein P, et al. Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2017; 6:173–90.
80 80 Schulz S, Richardt G, Laugwitz K‐L, et al. Prasugrel plus bivalirudin vs clopidogrel plus heparin in patients with ST‐segment elevation myocardial infarction. Eur Heart J 2014; 35:2285–94.
81 81 Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017; 377:1132–42.
82 82 Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2019; 93:241–7.
83 83 Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel‐eluting stents versus bare‐metal stents in acute myocardial infarction (HORIZONS‐AMI): final 3‐year results from a multicentre, randomised controlled trial. The Lancet 2011; 377:2193–204.
84 84 Stone GW, Clayton T, Deliargyris EN, et al. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS‐AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). J Am Coll Cardiol 2014; 63:15–20.
85 85 Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218–30.
86 86 Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369:2207–17.
87 87 Dauerman HL, Frederick PD, Miller D, French WJ. Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis 2007; 18:141–8.
88 88 Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT‐PPCI): an open‐label, single centre, randomised controlled trial. The Lancet 2014; 384:1849–58.
89 89 Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313:1336–46.
90 90
